Grünenthal Announces Exclusive License Agreement for Commercialization of Innovative Surgical Glue in the EU and Latin America

AACHEN, Germany, May 11, 2016 /PRNewswire/ --

• Agreement underpins Grünenthal's strategy to strengthen its portfolio for the European hospital market 

The Grünenthal Group today announced an exclusive license and supply agreement with Adhesys Medical Inc., USA, on the commercialization of an innovative topical skin adhesive. With this agreement, Grünenthal acquires the exclusive distribution rights for the EU and Latin American markets. Both companies pursue the common objective to launch a medical device that meets highest standards. A key element is the conduct of appropriate clinical trials, which the partners will pursue together. The agreement is another step in Grünenthal's strategy to broaden its portfolio for the hospital market. The latest milestone in this strategy was the launch of Zalviso^®, a non-invasive pre-programmed system for patient-controlled analgesia for the management of acute moderate to severe post-operative pain. 

"We are very pleased to announce the partnership with Adhesys Medical. With the innovative surgical glue, we will be able to offer surgeons and patients an alternative in the area of topical wound closure," states Klaus-Dieter Langner, PhD. and Chief Scientific Officer of the Grünenthal Group. "Partnerships are very vital for Grünenthal's success. The agreement with Adhesys Medical is another proof point for our successful approach to partnering: Transparent, long-term orientation, agility and creativity in deal-making as well as working together on eye-level," Langner concludes.

"The commercialization of our first product will be a great step for us and we are excited to have a strong partner on our side," says Marius Rosenberg, CEO and Founder of Adhesys Medical.

The innovative surgical glue is designed for wound closure on the skin. The polyurethane-based technology is unique, as it combines strength and flexibility. This combination of features allows for use in a wide variety of surgical procedures and will provide an alternative to common methods of wound closure such as sutures and staples.

As a privately owned mid-cap pharmaceutical company, Grünenthal has a long track-record of successful partnerships and wants to build on this success to achieve maximum growth and revenues in its core business pain while expanding additional growth indications. This includes post-operative care therapies that fit Grünenthal's current target groups in the European hospital market.

About Grünenthal 

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.

Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5,300 employees are working for the Grünenthal Group worldwide. In 2015, Grünenthal achieved revenues of € 1.2 bn. More information: http://www.grunenthal.com.

Contact: Steffen Fritzsche, Head Corporate Communications
Tel.: +49-241-569-1335, [email protected]

Grünenthal GmbH, 52099 Aachen, Germany, http://www.grunenthal.com

SOURCE Grunenthal Pharma GmbH & Co. KG.